You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

You’ve been redirected to the new Cancer Care Ontario website. You can also visit the archived website, which is no longer being maintained.

Guidelines & Advice
About Guidelines Email Guidelines Team

Strategies of Sequential Therapies in Unresectable, Metastatic Colorectal Cancer Treated with Palliative Intent

ID: 2-5 Jan 2014
Type of Content: Guidelines & Advice, Clinical
Document Status: Current
Authors:
T. Asmis, S. Berry, R. Cosby, K. Chan, N. Coburn, M. Rother , Gastrointestinal Disease Site Group

Patient Population

Adult patients (≥18 years old) with unresectable metastatic colorectal cancer.

Intended Guideline Users

Clinicians and healthcare providers involved in the management of patients with unresectable, metastatic colorectal cancer treated with palliative intent.

Research Question(s)

What is the impact of different strategies of sequential and combination chemotherapy on efficacy (including overall survival), toxicity and quality of life in unresectable metastatic colorectal cancer treated with palliative intent?

The cytotoxic agents covered in this guideline include initial fluoropyrimidine (5-FU or capecitabine) either alone or in combination, irinotecan and oxaliplatin.

pdf download Summary (PDF) (173.19 KB)
pdf download Full Report (PDF) (581.78 KB)